Medtronic, a global leader in healthcare technology, announced a partnership with Methinks AI, a leading AI-driven radiological triage and notification system provider to enhance stroke treatment across Central and Eastern Europe, Africa, Türkiye and Middle East, supporting its Neurovascular business.
醫療技術領域的全球領導者美敦力宣佈與領先的AI驅動放射學分診和通知系統提供商Methinks AI合作，以加強中歐、東歐、非洲、土耳其和中東地區的中風治療，支持其神經血管業務。
Financial terms of the partnership were not disclosed..
合作關係的財務條款尚未披露。
This collaboration highlights the critical role of services and solutions in optimizing procedural support and patient pathways in stroke care.
此次合作突顯了服務和解決方案在優化中風護理的程序支持和患者路徑方面的關鍵作用。
For Medtronic, this partnership aligns with its commitment to delivering cutting-edge innovations in acute ischemic stroke treatment. Medtronic has been at the forefront of stroke therapy with its advanced stent retrievers and aspiration systems for clot retrieval. Methinks AI-powered solutions supports healthcare professionals with stroke diagnostics, ultimately helping to save critical time in patient management..
對於美敦力而言，該合作符合其在急性缺血性卒中治療領域提供前沿創新技術的承諾。美敦力憑藉其先進的支架取栓器和抽吸系統，在卒中治療領域處於領先地位。Methinks 的人工智能解決方案爲醫療專業人員提供卒中診斷支持，最終有助於節省患者管理的關鍵時間。
Methinks AI solutions, which has already been validated in renowned hospitals across Europe and the U.S., stands out for its ability to detect over 80% of large vessel occlusions using only non-contrast CT imaging. This capability ensures faster diagnosis, even in settings with limited access to advanced imaging technologies, reducing critical delays in treatment.
我認爲，已經在歐洲和美國的知名醫院得到驗證的AI解決方案，以其僅使用非對比CT成像就能檢測出超過80%的大血管閉塞的能力而脫穎而出。這種能力確保了即使在缺乏先進成像技術的環境下也能更快地進行診斷，從而減少治療中的關鍵延誤。
Furthermore, Methinks AI has partnered with Microsoft to enhance the scalability and accessibility of this technology..
此外，Methinks AI 已與微軟合作，以增強該技術的可擴展性和可訪問性。
By integrating Methinks AI with Medtronic stroke treatment portfolio, the partnership will streamline the connectivity between stroke centers and regional hospitals in the region, enabling seamless patient triage and care coordination. The software capability to assess strokes directly from a non-contrast CT scan will empower healthcare providers with timely decision-making tools..
通過將Methinks AI與美敦力的中風治療產品組合相結合，此次合作將簡化區域內中風中心與地方醫院之間的連接，實現無縫的患者分診和護理協調。該軟件能夠直接從非對比CT掃描中評估中風，將爲醫療保健提供者提供及時的決策工具。
The future of stroke management
卒中管理的未來
This collaboration marks a significant step in patient pathway development for medical centers in the region. The integration of AI-driven stroke diagnostics with Medtronic Neurovascular products is expected to accelerate therapy adoption, bringing stroke treatment to a new level of efficiency.
此次合作標誌着該地區醫療中心在患者診療路徑發展上邁出了重要一步。將人工智能驅動的中風診斷與美敦力神經血管產品相結合，有望加速治療方案的採用，使中風治療效率邁上新臺階。
“At Medtronic, we are committed to providing innovative solutions that extend beyond traditional product offerings. This partnership reinforces our commitment to support healthcare professionals with advanced stroke care tools, ensuring faster and more effective treatment for patients across the region and transforming stroke care by combining breakthrough AI diagnostics with world-class medical device solutions”, said Maria Zvereva, Neurovascular strategic marketing leader in CEMA region, which is part of the Neuroscience Portfolio at Medtronic..
“在美敦力，我們致力於提供超越傳統產品供應的創新解決方案。此次合作加強了我們對醫療專業人員的支持承諾，通過先進的卒中護理工具確保區域內患者獲得更快速、更有效的治療，並通過將突破性的人工智能診斷與世界級的醫療器械解決方案相結合，徹底改變卒中護理。” 美敦力神經科學業務組合中CEMA地區神經血管戰略營銷負責人瑪麗亞·茲韋列娃表示。
'We are honored to collaborate with Medtronic, a company that shares our commitment to increasing the number of stroke treatments available to those that urgently need them. Together, we aim to bring our AI-driven solutions to more hospitals to benefit from early triage and efficient coordination,' said Pau Rodríguez, CEO of Methinks..
“我們很榮幸能與美敦力合作，這是一家與我們一樣致力於增加中風治療數量以幫助那些迫切需要的患者的公司。通過合作，我們旨在將我們的人工智能驅動解決方案推廣到更多醫院，以受益於早期分診和高效協調，”Methinks首席執行官Pau Rodríguez表示。
About Methinks AI
關於Methinks AI
Methinks AI is a pioneering company in the development of artificial intelligence software for the early assessment of stroke. It is the first CE-marked medical device capable of detecting large vessel occlusions, both hyperdense and non-hyperdense, as well as intracerebral hemorrhages using non-contrast computed tomography.
Methinks AI是一家在開發用於中風早期評估的人工智能軟件領域的先鋒公司。它是首個獲得CE認證的醫療設備，能夠使用非增強計算機斷層掃描檢測大血管阻塞（包括高密度和非高密度）以及腦出血。
This technology helps optimize stroke patient triage and reduce time to treatment, significantly improving clinical outcomes..
這項技術有助於優化中風患者的分診並縮短治療時間，從而顯著改善臨牀結果。
About Medtronic
美敦力公司簡介
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.
大膽思考。更大膽行動。我們是美敦力。美敦力公司總部位於愛爾蘭戈爾韋，是全球領先的醫療技術公司，通過尋找和發現解決方案，勇敢地應對人類面臨的最嚴峻的健康問題。我們的使命——減輕病痛、恢復健康、延長生命——團結了遍佈150多個國家的95,000多名充滿熱情的員工。
Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.
我們的技術和療法治療70種健康狀況，包括心臟設備、手術機器人、胰島素泵、手術工具、患者監測系統等。憑藉我們多樣化的知識、無盡的好奇心和幫助所有需要幫助的人的願望，我們提供了創新技術，每秒、每小時、每一天都在改變兩個人的生活。
Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .
隨着我們助力洞察驅動的護理、以人爲本的體驗以及爲我們的世界帶來更好的結果，期待我們做出更多貢獻。在我們所做的一切中，我們正在創造非凡。欲瞭解有關美敦力的更多信息，請訪問。
www.Medtronic.com
www.美敦力.com
and follow us on
關注我們
領英
.
。
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
任何前瞻性陳述均受風險和不確定性的影響，例如美敦力向證券交易委員會提交的定期報告中所述的風險和不確定性。實際結果可能與預期結果有重大差異。
Contacts:
聯繫人：
Malgorzata Kolodrub
馬爾戈扎塔·科洛德魯布
Public Relations
公共關係
+0048 887 856 679
+0048 887 856 679
Ryan Weispfenning
瑞安·魏斯芬寧
Investor Relations
投資者關係
+1-763-505-4626
+1-763-505-4626